Comparison of Chemotherapy With PD-1/L1 or CTLA-4 Inhibitors Alone Or In Combination In Advanced Or Metastatic Non-Small Cell Lung Cancer: A Meta- Analysis

Lihu Gu

HwaMei Hospital, University of Chinese Academy of Sciences

Jiali Liang

Zhejiang Chinese Medical University

Wei Dai

Zhejiang Chinese Medical University

Jiayu Li

Zhejiang Chinese Medical University

Yuexiu Si

Zhejiang Chinese Medical University

Wei Ren

Zhejiang Chinese Medical University

Yan Lu

Zhejiang Chinese Medical University

Ping Chen (✉ sap20182021@163.com)

HwaMei Hospital, University of Chinese Academy of Sciences

Research Article

Keywords: NSCLC, PD-1/L1, CTLA-4, Chemotherapy, Meta-analysis

Posted Date: September 20th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-855827/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: In spite of the wide use of immune-checkpoint inhibitors (ICIs) in advanced or metastatic non-small cell lung cancer (NSCLC), whether ICIs or conventional chemotherapy is more effective still remains controversial. This study was conducted to evaluate the efficacy of giving patients programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte protein 4 (CTLA-4) alone or in their combination (PD-1/L1 + CTLA-4) versus simply applying chemotherapy in patients with advanced or metastatic NSCLC.

Methods: This meta-analysis was conducted from PubMed, Web of Science, Medline, Embase, and the Cochrane Library up to March 2021 to identify relevant randomized controlled trials (RCTs). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoint was adverse events (AEs).

Results: The search process has identified 13 studies containing 7918 patients with advanced or metastatic NSCLC. The benefit of PD-1/L1 or CTLA-4 inhibitors alone or in combination compared with chemotherapy for advanced or metastatic NSCLC was elucidated in both overall survival (OS) [HR=0.75, 95%CI (0.70-0.80), P<0.001] and progression-free survival (PFS) [HR=0.83, 95%CI (0.73-0.95), P<0.001]. Sex is another vital factor that affects the efficacy of ICIs. Male [HR=0.71, 95%CI (0.63-0.81)] benefits more from ICIs than the female [HR 0.80, 95%CI (0.68-0.94)] in OS. Besides, ICIs were associated with fewer AEs compared to chemotherapy.

Conclusion: PD-1/L1 or CTLA-4 inhibitors alone or in combination, with fewer AEs, was associated with significant improvements in terms of OS and PFS than chemotherapy in treatment of advanced or metastatic NSCLC.

Introduction

Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer-related death in 2020, to be more precise, the diagnosis rate was approximately 1 in 10 (11.4%), and the mortality rate was nearly 1 in 5 (18.0%) deaths worldwide. Additionally, about 85% of the lung cancer patients had what so called non-small cell lung cancer (NSCLC), which is one of the histological subtypes of lung cancer. NSCLC can be further sub-categorized into squamous cell carcinoma, adenocarcinoma and large cell carcinoma. About 75% of NSCLC patients are already in advanced or metastatic stage when they are diagnosed, and the 5-year survival rate is unfortunately low.^[1]

Applying cisplatin-based chemotherapy concurrently with radiotherapy is currently the standard treatment guideline for advanced or metastatic NSCLC patients. However, the survival outcome was still disappointing.^[2] Thus, improvements in treatment guideline for patients with advanced or metastatic NSCLC are urgently needed. With the use of immune checkpoint inhibitors (ICIs) in advanced or metastatic NSCLC, a number of studies have shown that the therapeutic effect of combine ICIs in chemotherapy is superior compared with conventional chemotherapy only, but the improvement is at the cost of increased adverse events (AEs).^[3] The best-known ICIs are programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte protein 4 (CTLA-4). Herein, we investigated the efficacy and safety of adding PD-1/L1 or CTLA-4 inhibitors alone and the combination (PD-1/L1 + CTLA-4) compared with only giving chemotherapy in patients with advanced or metastatic NSCLC.

Materials And Methods

Search strategy

This meta-analysis was conducted from PubMed, Web of Science, Medline, Embase, and the Cochrane Library as of March 2021 to find relevant studies. A combination of free text words and medical subject words was used to complete the subtopic search. Search criteria includes ("nivolumab" OR "ipilimumab" OR "sintilimab" OR "tislelizumab" OR "cemiplimab" OR "camrelizumab" OR "BMS 936558" OR "BMS 936559" OR "pembrolizumab" OR "lambrolizumab" OR "MK 3475" OR "pidilizumab" OR "CT 011" OR "durvalumab" OR "MEDI 4736" OR "atezolizumab" OR "MPDL 3280a" OR "avelumab" OR "AMP 224" OR "PD-1" OR "PD-L1" OR "B7-H1" OR "CD274" OR "programmed death 1" OR "programmed death ligand 1" OR "CTLA-4 Antigen"[Mesh]) AND ("lung tumor" OR "lung cancer" OR "lung carcinoma" OR "lung neoplasm" OR "lung malignancy" OR "lung sarcoma" OR "Lung Neoplasms"[Mesh] OR "Carcinoma, Non-Small-Cell Lung" OR "squamous cell lung carcinoma" OR "lung adenocarcinoma" OR "large cell lung carcinoma"). Two researchers independently screened the titles, abstracts, and references of the retrieved articles.

Study selection and quality assessment

Studies that were included meet the following criteria. (a) Type of literature: Phase II/III randomized controlled trials (RCTs); (b) Patients involved in the study were diagnosed with advanced or metastatic NSCLC; (c) The intervention group was treated only with PD-1/L1 or CTLA-4 inhibitors alone or their combination. The control group was treated only with chemotherapy. (d) Data is available. Exclusion criteria

are as follow. (a) Non-English articles; (b) Neoadjuvant therapy is involved in the treatment process; (c) The intervention group used immunotherapy in combination with other treatment methods, such as chemotherapy or radiotherapy; (d) Articles with the same research population. As for the last exclusion case, we analyzed the latest or most complete data available.

Methodological quality was assessed for the included clinical trials via the Cochrane Collaboration Tool. Each eligible study was appraised predominantly in six aspects: (a) the sequence generation; (b) allocation concealment; (c) blinding; (d) incomplete outcome data; (e) selective outcome reporting; (f) free of other bias. Risk of bias was assessed and categorized as “low risk”, “high risk” or “unclear risk”.

Data extraction

The data for each study were extracted independently by two researchers. Unified opinions were reached by consulting a third researcher. The following information was used: (a) author, year of publication, treatment stage, intervention, medicine, follow-up time, and sample size; (b) patient gender, age, histological type of tumor, and PD-1/L1 tumor proportion score (TPS); (c) the primary outcome was overall survival (OS) and progression-free survival (PFS). The secondary outcome was AEs. This meta-analysis was conducted in accordance with the preferred report project guidelines provided by the Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) 2015^[4].

Data analysis and statistical methods

Hazard ratios (HR) and 95% confidence intervals (CI) were calculated to support OS and PFS. Risk ratios (RR) and 95%CI were calculated to support AEs. I^2 statistics were used to assess heterogeneity between studies. In order to investigate the sources of heterogeneity, predefined subgroup analyses were performed. Due to the complexity of control conditions and the diversity of therapeutic agents, random effects model was applied to improve the reliability of the results in this article. Sensitivity analysis was performed to verify the stability of the results. Egger's test ($P < 0.1$) was used to evaluate publication bias. All the above meta-analyses were performed via Stata SE Version 12 (Stata Corporation). All the above statistical tests were bilateral, and $P < 0.05$ was considered as a statistically significant difference in mentioned parameters.

Results

Eligible studies

20309 relevant clinical records were generated based on the search strategy. After screening and qualification assessment, a total of 13 qualified phase II/III RCTs^[5–17], including 7918 patients with advanced or metastatic NSCLC, were selected to complete this meta-analysis. The detailed investigation and research selection process was shown in Fig. 1.

Study characteristics and quality

The basic characteristics of the selected studies were shown in Table 1. All the intervention groups in the selected studies used PD-1 inhibitor ($n = 7$), PD-L1 inhibitor ($n = 5$), or PD-1/L1 + CTLA-4 inhibitors ($n = 2$); the control group used chemotherapy alone, among which half of them used docetaxel. There is no RCTs of using CTLA-4 inhibitor alone in the studies involved. Patients included in this study had two histological types: squamous and non-squamous. Besides, there were 7^[5, 6, 7, 8, 10, 11, 16] studies with non-first-line treatment and 6^[9, 12, 13, 14, 15, 17] studies with first-line treatment. In addition, clinical trials with high methodological quality were evaluated via using the Cochrane Collaboration Tool. The evaluation results were shown in Supplementary Table 1.

Table 1
Characteristics of included clinical trials in the meta-analysis.

Author, Year	Trial Phase	Median follow-up time	Histology	TPS	Line	Therapeutic regimen		Number of patients	
						Treatment	Control	Treatment	Control
Borghaei, H. 2015	3	NA	non-squamous	all	non-first	nivolumab	docetaxel	292	290
Brahmer, J. 2015	3	12 months	squamous	all	non-first	nivolumab	docetaxel	135	137
Herbst, Roy S. 2016	2/3	NA	squamous or non-squamous	positive	non-first	pembrolizumab	docetaxel	690	340
Fehrenbacher, Louis. 2016	2	NA	squamous or non-squamous	all	non-first	atezolizumab	docetaxel	144	133
Reck, M. 2016	3	11.2 months	squamous or non-squamous	≥ 50%	first	pembrolizumab	platinum-based chemotherapy	154	151
Rittmeyer, Achim. 2017	3	21 months	squamous or non-squamous	all	non-first	atezolizumab	docetaxel	425	425
Barlesi, Fabrice. 2018	3	NA	squamous or non-squamous	all	non-first	avelumab	docetaxel	396	396
Mok, Tony S. K. 2019	3	12.8 months	squamous or non-squamous	≥ 1%	first	pembrolizumab	chemotherapy	637	637
Hellmann, M. D. 2019	3	24 months	squamous or non-squamous	≥ 1%	first	nivolumab + ipilimumab	chemotherapy	396	397
Herbst, R. S. 2020	3	13.4 months	squamous or non-squamous	all	first	atezolizumab	chemotherapy	277	277
Rizvi, N. A. 2020	3	NA	squamous or non-squamous	≥ 25%	first	durvalumab	platinum-based chemotherapy	163	162
						durvalumab + tremelimumab	platinum-based chemotherapy	163	162
Lu, S. 2021	3	25.9 months	squamous or non-squamous	all	non-first	nivolumab	docetaxel	338	166
Sezer, Ahmet. 2021	3	NA	squamous or non-squamous	≥ 50%	first	cemiplimab	platinum-doublet chemotherapy	283	280
NA: not available									
TPS: PD-1/L1 tumour proportion score									

Analysis of OS

OS was reported in all the included studies. Compared with chemotherapy alone, PD-1/L1 or CTLA-4 inhibitors alone or in combination (PD-1/L1 + CTLA-4) had been proved to be capable to prolong OS in patients with advanced or metastatic NSCLC [HR = 0.75, 95%CI (0.70–0.80), $P < 0.001$], as being detailly showed in Fig. 2. PD-1/L1 or CTLA-4 inhibitors alone or in combination compared with chemotherapy alone could improve OS of patients both in the first [HR = 0.77, 95%CI (0.70–0.84)] and non-first line treatment [HR = 0.74, 95%CI (0.67–0.81)] (Fig. 3). As for different targets, PD-1 inhibitors [HR = 0.70, 95%CI (0.64–0.78)], PD-L1 inhibitors [HR = 0.80, 95%CI (0.72–0.88)], and PD-1/L1 + CTLA-4 inhibitors [HR 0.81, 95%CI (0.68–0.95)] have all improved the OS, and it seemed that the pharmacological effect of PD-1 inhibitors was more noticeable (Fig. 4). Among all of the relevant drugs, nivolumab [HR = 0.71, 95%CI (0.62–0.81)], pembrolizumab [HR = 0.72, 95%CI (0.61–0.85)], and atezolizumab [HR = 0.76, 95%CI (0.66–0.86)] had been used most commonly and all of them could extend OS in patients

with advanced or metastatic NSCLC, compared with chemotherapy alone (Fig. 5). In all the included studies, both male [HR = 0.71, 95%CI (0.63–0.81)] and female [HR 0.80, 95%CI (0.68–0.94)] could benefit from PD-1/L1 or CTLA-4 inhibitors alone or their combination (Fig. 6). Six studies collaboratively showed both patients < 65 years [HR = 0.74, 95%CI (0.66–0.82)] and patient ≥ 65 years [HR = 0.76, 95%CI (0.65–0.89)] could get a prolonged OS with PD-1/L1 or CTLA-4 inhibitors alone or their combination compared with chemotherapy alone (Fig. 7). PD-1/L1 and CTLA-4 inhibitors showed a greater improvement in OS than chemotherapy not only in patients with advanced or metastatic squamous NSCLC [HR = 0.76, 95%CI (0.67–0.87)], but also in patients with advanced or metastatic non-squamous lung cancer [HR = 0.66, 95%CI (0.58–0.76)] (Fig. 8). In these included studies, with PD-1/L1 or CTLA-4 inhibitors alone or their combination, both group of patients, with TPS ≥ 0.01 [HR = 0.76, 95%CI (0.71–0.82)] and TPS < 0.01 [HR = 0.75, 95%CI (0.58–0.97)] respectively, had a longer OS compared with patient group who were given chemotherapy only (Fig. 9).

Analysis of PFS

PFS was reported in 12 studies. Similar to OS, giving PD-1/L1 or CTLA-4 inhibitors alone or in combination resulted better in PFS than applying chemotherapy alone in patients with advanced or metastatic NSCLC [HR = 0.83, 95%CI (0.73–0.95), $P < 0.001$] (detailed data are shown in Supplementary Fig. 1). PD-1/L1 or CTLA-4 inhibitors alone or in combination was directly related to better clinical efficacy in both first-line [HR = 0.77, 95%CI (0.58–1.01)] and non-first line treatment [HR = 0.89, 95%CI (0.79–1.01)] (Supplementary Fig. 2). Among PD-1 [HR = 0.75, 95%CI (0.61–0.91)], PD-L1 [HR = 0.94, 95%CI (0.81–1.09)] and PD-1/L1 + CTLA-4 [HR = 1.05, 95%CI (0.72–1.53)] inhibitors, only PD-1 has showed a statistically significant improvement, comparing with chemotherapy alone, in PFS in patients with advanced or metastatic NSCLC (Supplementary Fig. 3). As for nivolumab [HR = 0.78, 95%CI (0.63–0.96)], pembrolizumab [HR = 0.79, 95%CI (0.57–1.11)], and atezolizumab [HR = 0.89, 95%CI (0.77–1.02)], only nivolumab has demonstrated a statistically significant improvement in PFS in advanced or metastatic NSCLC patients compared to chemotherapy alone (supplemental Fig. 4). In the study of PFS, only male patients [HR = 0.60, 95%CI (0.44–0.81)] who had received treatment with PD-1/L1 or CTLA-4 inhibitors alone or in their combination achieved better treatment outcomes than chemotherapy alone eventually. Female [HR = 1.06, 95%CI (0.72–1.57)] patients, on the other hand, have indicated no statistically significant improvement (Supplementary Fig. 5). When it comes to different age groups, PD-1/L1 or CTLA-4 inhibitors alone or their combination improved the efficacy of PFS both in patients < 65 years [HR = 0.72, 95%CI (0.54–0.95)] and ≥ 65 years [HR = 0.74, 95%CI (0.52–1.05)]. However, the difference was not statistically significant in the ≥ 65 years age group (Supplementary Fig. 6). As for histological types, both patients with squamous [HR = 0.61, 95%CI (0.48–0.77)] and patients with non-squamous [HR = 0.82, 95%CI (0.64–1.04)] had a longer survival if they were given PD-1/L1 or CTLA-4 inhibitors alone or in their combination comparing to those who had received chemotherapy alone. However, only patients with squamous subtype had statistically significant improvement in treatment outcomes (Supplementary Fig. 7). In these included studies, comparing pharmacological treatment with PD-1/L1 or CTLA-4 inhibitors alone or in combination with chemotherapy alone, there was a better prognosis in terms of PFS in patients with TPS ≥ 0.01 [HR = 0.82, 95%CI (0.65–1.03)] and patients with TPS < 0.01 [HR = 0.66, 95%CI (0.43–1.01)], though the difference is not statistically significant (Supplementary Fig. 8).

Analysis of AEs

Any grade or 3–5 grade AEs were extracted from 4184 patients in the trial group and 3506 patients in the control group. A total of 5794 patients who were classified in all 5 grades of AEs are covered in this meta-analysis. Since a large number of AEs types were reported, the most common AEs for analysis were selected and showed detailly in Table 2. Compared with controls, treatment with PD-1/PD-L1 or CTLA-4 inhibitors alone or in combination was associated with fewer AEs in any grades [RR = 0.77, 95%CI (0.70–0.84)] and AEs in 3–5 grade [RR = 0.41, 95%CI (0.31–0.54)]. This statistical difference was also observed in most common AEs, including neutropenia [any grade RR = 0.05; 3–5 grade RR = 0.03], fatigue [any grade RR = 0.55; 3–5 grade RR = 0.51], nausea [any grade RR = 0.30; 3–5 grade RR = 0.32] and decreased appetite [any grade RR = 0.53; 3–5 grade RR = 0.48]. Meanwhile, this statistical difference was not investigated in some other AEs, such as diarrhea, alopecia, and constipation. Besides, the incidence of rash in any grade of AEs [RR = 1.69, 95%CI (1.12–2.55)] did not have any advantage over the conventional chemotherapy, but there was no statistical difference in 3–5 grade RR rash [RR = 2.24, 95%CI (0.92–5.43)].

Table 2
Subgroup analysis of the adverse events (AEs).

Immunotherapy vs. chemotherapy	No. of studies	RR	95%CI	Heterogeneity (I ²) (%)
Any grade adverse events	11	0.77	0.70–0.84	93
Any grade fatigue	13	0.55	0.43–0.64	59
Any grade nausea	12	0.3	0.21–0.43	91
Any grade decreased appetite	13	0.53	0.42–0.67	79
Any grade asthenia	10	0.58	0.46–0.73	62
Any grade diarrhea	11	0.71	0.49–1.04	89
Any grade anemia	11	0.16	0.10–0.24	88
Any grade alopecia	10	0.02	0.01–1.03	0
Any grade neutropenia	12	0.05	0.03–0.07	38
Any grade febrile neutropenia	6	0.02	0.01–0.07	0
Any grade leukopenia	6	0.14	0.08–0.27	38
Any grade rash	9	1.69	1.12–2.55	74
Any grade vomiting	6	0.28	0.13–0.61	92
Any grade constipation	7	0.28	0.13–0.61	92
Any grade thrombocytopenia	6	0.08	0.05–0.14	4
Any grade 3 or higher adverse events	11	0.41	0.31–0.54	93
Grade 3 or higher fatigue	13	0.51	0.35–0.75	26
Grade 3 or higher nausea	12	0.32	0.17–0.60	2.8
Grade 3 or higher decreased appetite	13	0.48	0.29–0.80	0
Grade 3 or higher asthenia	10	0.28	0.17–0.48	0
Grade 3 or higher diarrhea	11	0.75	0.32–1.78	63
Grade 3 or higher anemia	11	0.12	0.06–0.21	60
Grade 3 or higher alopecia	10	0.16	0.04–0.61	0
Grade 3 or higher neutropenia	12	0.03	0.02–0.05	0
Grade 3 or higher febrile neutropenia	6	0.02	0.01–0.07	0
Grade 3 or higher leukopenia	6	0.06	0.02–0.15	0
Grade 3 or higher rash	9	2.24	0.92–5.43	0
Grade 3 or higher vomiting	6	0.23	0.08–0.65	0
Grade 3 or higher constipation	7	0.98	0.29–3.29	0
Grade 3 or higher thrombocytopenia	6	0.04	0.02–0.12	0
RR: risk ratio; CI: confidence interval.				

Publication bias and sensitivity analysis

When it comes to OS, no significant publication bias was elucidated via Egger's test ($P = 0.126$, Supplementary Fig. 9), and sensitivity analysis indicated that the result was insensitive to the included studies (Supplementary Fig. 10). As for PFS, Egger's test showed that there was no statistically significant publication bias ($P = 0.1$, Supplementary Fig. 11), and sensitivity analysis indicated that the result was insensitive to included studies (Supplementary Fig. 12).

Discussion

With the gradual application of ICIs in treating advanced or metastatic NSCLC, the awareness of ICIs' efficacy has been widely raised by scientists and researchers. Previous studies have shown that ICIs combined with chemotherapy can effectively improve survival in patients with advanced or metastatic NSCLC compared to single treatment of conventional chemotherapy, suggesting that ICIs are really effective in patients with advanced or metastatic NSCLC^[18]. But the efficacy of ICIs versus conventional chemotherapy remains controversial.

PD-1/L1 inhibitors and CTLA-4 inhibitors are considered as the promising ones of ICIs at present. Herein, the meta-analysis was conducted to evaluate the efficacy of PD-1/L1 or CTLA-4 inhibitors alone or in combination (PD-1/L1 + CTLA-4) versus conventional chemotherapy in patients with advanced or metastatic NSCLC, setting up PFS as and OS as primary endpoints and AEs as secondary endpoints. The results suggested that PD-1/L1 or CTLA-4 inhibitors alone or in combination can improve OS as well as PFS and these advantageous outcomes are in relationship with fewer AEs in patients with advanced or metastatic NSCLC compared to conventional chemotherapy. The results also elucidated that patients can benefit differently from ICIs depending on their disease subgroups. Sensitivity analysis indicated that the results is in good stability.

The pharmacological mechanism of ICIs had been discovered in several studies and has been confirmed in clinical studies. PD-1/L1 inhibitors can block the competitive binding of PD-1 and PD-L1, resulting in the up-regulation T cells in terms of growth and proliferation. This up-regulation leads to the improvement in T cells' recognition to tumor cells, then activates the immune function, to be more precise, attack and specifically kill tumour cells. In other words, the anti-tumor effect of ICIs is achieved by mobilizing the body's own immune function. Several preclinical studies^[19] have shown that blocking CTLA-4 can restore the activity of T cells and drastically prolong the survival time of memory T cells, hence restoring the body's immune function against tumor cells and improving the control rate of tumor. One of the biggest advantages of using immunotherapy over chemotherapy is that the pharmacological effect of immunotherapy can be long-lasting. In melanoma, a large number of super-survivors have a more than 10-year survival after clinical intervention and are clinically cured. Furthermore, in the study of Yixin Zhou^[20], PD-1/PD-L1 inhibitor plus chemotherapy, compared with chemotherapy, has contributed to improved PFS and OS in first-line therapy in NSCLC, but at the expense of increase in treatment-related AEs. However, in this research, PD-1/L1 or CTLA-4 inhibitors alone or in combination seemed to merit over chemotherapy alone not only in promoting survival time but also in reducing drug AEs in NSCLC patients. To conclude, patients with advanced or metastatic NSCLC seem to benefit more from ICIs compared to conventional chemotherapy.

Obviously, the effect of ICIs depends on the how functional the patient's autoimmune system is, which may be related to treatment lines. Herein, the first-line immunotherapy appears to be more helpful improving PFS in patients compared to the non-first line ICIs. The research results of Ma Amrein^[21] et al show that traditional platinum-contained chemotherapy would have negative impact on the immune microenvironment. Therefore, patients with different treatment lines would have different cell signaling process depending on their autoimmune function due to different times of treatment. To conclude, immunotherapy seems to be very promising on the first line because repeated use of chemotherapy would make more immune compromised patients, which is harmful and a potential burden to national health system. The immune function is the most vital factor that need to be considered when deciding whether the first-line treatment of NSCLC patients should be chemotherapy or immunotherapy.

In addition, previous studies have suggested that the efficacy of ICIs is associated with TPS of patients. It is generally believed that TPS has a predictive effect on the efficacy of ICIs in NSCLC patients^[22]. Unfortunately, this trend has not been found here. This may result from the small sample size in research process. Common thresholds for TPS classification include 1%, 50%, etc., so another rational assumption is that the dissimilarity may due to the not appropriate threshold for grouping scheme which is 1% in this study. Since distinction in classification criteria of defining high and low expression of TPS may lead to different therapeutic effects as well as prognosis judgment, it is very necessary to determine a recognized and effective classification threshold.

No matter first-line or second-line treatment for advanced or metastatic NSCLC, there are promising PD-1 inhibitors and PD-L1 inhibitors in clinical treatment. Previous studies have shown that the effect of PD-1 inhibitors and PD-L1 inhibitors in improving OS, in patients with NSCLC, are similar^[23]. However, in this study, the effects of the different inhibitors seemed to result differently in prognosis. Undeniably, it is reasonable to suspect the advantage of ICIs due to the lack in enough RCTs being conducted with PD-L1 inhibitors. But among the most commonly used three ICIs, nivolumab, pembrolizumab, and atezolizumab, both PD-1 inhibitors (nivolumab and pembrolizumab) have better pharmacological effects than the PD-L1 inhibitor (atezolizumab). We seemed to have reached the same conclusion that PD-1 inhibitors are more promising in treating patients with advanced or metastatic NSCLC. Theoretically, PD-1 antibody can bind to PD-1 protein on T cells' cell membrane. This process will block the binding between PD-1 and PD-L1 / PD-L2 at the same time. PD-L1 antibody, however, can only interact with PD-L1 and specifically block the binding between PD-1 and PD-L1. Therefore, T cells might still be inhibited by the interaction between PD-1 and PD-L2 using anti-PD-L1 treatment^[24]. All above proved the presumed theory that PD-1 inhibitors showed greater potential

than PD-L1 inhibitors in treating patients with advanced or metastatic NSCLC, which may be related to the subtle differences in the mechanism of action between PD-1 antibodies and PD-L1 antibodies.

The therapeutic effect of ICIs is influenced not only by drug types, but also by the biological characteristics of patients, including male and female. Compared to no significant differences being observed between age subgroups, the distinction between genders is obvious. Male with advanced or metastatic NSCLC appears to benefit more from ICIs than the female in this study. There may be several rational reasons leading to this dissimilarity. Firstly, the incidence of tumor histology of NSCLC in male and female are different, to be more detailed, female is more likely to be diagnosed with adenocarcinoma^[25], which is more sensitive to chemotherapy than squamous NSCLC^[26]. Hence, female tends to benefit less than male in treatment with ICIs. Moreover, some other studies have revealed the potential impact of estrogen on tumor development. The estrogen content in females was significantly higher than that in males. As for women in different ages, the therapeutic effect can be difference as well. Survival of postmenopausal female undergoing chemotherapy is better, but premenopausal female tends to have a worse prognosis than postmenopausal female and the male^[27]. Besides, several studies have suggested that estrogen upregulates both PD-1 and PD-L1 and may play an important role in the PD-1 / PD-L1 signal pathway^[28, 29]. These sex-based immunological differences may be the reason why the male in this study benefits more from ICIs than female. Therefore, how sex affects the therapeutic effect of immunotherapy in cancer treatment is what need to be focused in future studies.

Encouragingly, in addition to therapeutic efficacy, ICIs also outperform conventional chemotherapy in terms of AEs in treatment of advanced or metastatic NSCLC. In this study, comparing with conventional chemotherapy, ICIs not only obviously improve survival time in patients with advanced or metastatic NSCLC, but also decrease the incidence of a majority of AEs. In this analysis, most RCTs chose paclitaxel or platinum as chemotherapy agents. According to previous studies, although paclitaxel and docetaxel are clinically active in NSCLC chemotherapy, they are problematic due to relating severe dose-limiting toxicity, the most prominent among which is neutropenia^[30, 31]. In this research, PD-1/L1 or CTLA-4 inhibitors alone or in combination significantly decreased the incidence of neutropenia compared to the incidence of that in patients treated with chemotherapy. On the other hand, PD-1/L1 or CTLA-4 inhibitors alone or in combination is associated with a higher incidence of rashes, which may be related to immunologic derangement. But there was no significant difference in the incidence of severe rash between treatment groups with immunotherapy or chemotherapy. Overall, the incidence of adverse reactions in patients' NSCLC treatment is lower in immunotherapy than in chemotherapy.

There are some limitations in this study. First of all, the sample sizes of included studies were not exactly same. Studies with small sample sizes may be one of the limits in the credibility of results. Secondly, some important gene mutation indicators, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), have been reported to be essential in affecting the therapeutic effect of PD-1/L1 inhibitors. Unfortunately, the related analysis is failed to be performed due to insufficient data. Moreover, most of the patients enrolled in this meta-analysis were from the West, and numerous parallel studies in Asia and other regions are in need. Of course, in order to explore the efficacy of PD-1/L1 or CTLA-4 inhibitors alone or in combination more comprehensively, more studies and analyses should be conducted to compare with other mainstream therapies such as radiotherapy.

To sum up, PD-1/L1 or CTLA-4 inhibitors alone or in combination have a better therapeutic effect and fewer AEs than conventional chemotherapy in patients with advanced or metastatic NSCLC. But the accurate therapeutic effect varies among different subgroups, such as different sex groups. These findings have a positive impact on the promising application of ICIs and are important in clinical practice when it comes to giving patients advice and helping clinicians decide appropriate treatment options.

Abbreviations

ICIs: immune-checkpoint inhibitors; NSCLC: non-small cell lung cancer; PD-1: programmed cell death 1; PD-L1: programmed cell death ligand 1; CTLA-4: cytotoxic T-lymphocyte protein 4; RCTs: randomized controlled trials; OS: overall survival; PFS: progression-free survival; AEs: adverse events; NA: not available; TPS: PD-1/L1 tumor proportion score; RR: risk ratio; CI: confidence interval; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent to publish

Not applicable.

Availability of data and materials

Data supporting findings reported in this study are available in the supplementary materials.

Competing interests

The authors declare no conflict of interest.

Funding

The authors received no financial support in conducting this meta-analysis.

Acknowledgments

Not applicable.

Authors' contributions

Each author contributed significantly to concept and development of the present paper. LHG and PC designed the research process. JLL and WD searched the database for corresponding articles and extracted useful information from the articles above. JYL and YXS used statistical software for analysis. WR and YL drafted the meta-analysis. All authors had read and approved the manuscript and ensured that this was the case.

References

1. Sung, H., et al. (2021). "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries." *CA Cancer J Clin* **71**(3): 209–249.
2. Eberhardt, W. E., et al. (2015). "2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer." *Ann Oncol* **26**(8): 1573–1588.
3. Zhou, Y., et al. (2018). "Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis." *J Immunother Cancer* **6**(1): 155.
4. Shamseer, L., et al. (2015). "Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation." *Bmj* **350**: g7647.
5. Borghaei, H., et al. (2015). "Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer." *N Engl J Med* **373**(17): 1627–1639.
6. Brahmer, J., et al. (2015). "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer." *N Engl J Med* **373**(2): 123–135.
7. Fehrenbacher, L., et al. (2016). "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial." *The Lancet* **387**(10030): 1837–1846.
8. Herbst, R. S., et al. (2016). "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial." *The Lancet* **387**(10027): 1540–1550.
9. Reck, M., et al. (2016). "Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer." *N Engl J Med* **375**(19): 1823–1833.
10. Rittmeyer, A., et al. (2017). "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial." *The Lancet* **389**(10066): 255–265.
11. Barlesi, F., et al. (2018). "Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study." *The Lancet Oncology* **19**(11): 1468–1479.
12. Hellmann, M. D., et al. (2019). "Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer." *N Engl J Med* **381**(21): 2020–2031.
13. Mok, T. S. K., et al. (2019). "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial." *The Lancet* **393**(10183): 1819–1830.
14. Herbst, R. S., et al. (2020). "Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC." *N Engl J Med* **383**(14): 1328–1339.

15. Rizvi, N. A., et al. (2020). "Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial." *JAMA Oncol* **6**(5): 661–674.
16. Lu, S., et al. (2021). "Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)." *Lung Cancer* **152**: 7–14.
17. Sezer, A., et al. (2021). "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial." *Lancet* **397**(10274): 592–604.
18. Kato, R., et al. (2020). "Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)." *J Immunother Cancer* **8**(1).
19. Peggs, K. S., et al. (2009). "Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies." *J Exp Med* **206**(8): 1717–1725.
20. Zhou, Y., et al. (2018). "Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis." *J Immunother Cancer* **6**(1): 155.
21. Amrein, M. A., et al. (2021). "Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study." *Cancer Immunol Immunother* **70**(2): 405–415.
22. Woodford, R., et al. (2019). "Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer." *Future Oncol* **15**(20): 2371–2383.
23. Bozcuk, H., et al. (2021). "Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer." *J Oncol Pharm Pract* **27**(2): 405–413.
24. Chen, L. and X. Han (2015). "Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future." *J Clin Invest* **125**(9): 3384–3391.
25. Jemal, A., et al. (2018). "Higher Lung Cancer Incidence in Young Women Than Young Men in the United States." *N Engl J Med* **378**(21): 1999–2009.
26. Schabath, M. B. and M. L. Cote (2019). "Cancer Progress and Priorities: Lung Cancer." *Cancer Epidemiol Biomarkers Prev* **28**(10): 1563–1579.
27. Stapelfeld, C., et al. (2020). "Sex-specificity in lung cancer risk." *Int J Cancer* **146**(9): 2376–2382.
28. Yang, L., et al. (2017). "Posttranscriptional Control of PD-L1 Expression by 17beta-Estradiol via PI3K/Akt Signaling Pathway in ERalpha-Positive Cancer Cell Lines." *Int J Gynecol Cancer* **27**(2): 196–205.
29. Polanczyk, M. J., et al. (2007). "Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)." *Int Immunol* **19**(3): 337–343.
30. Yared, J. A. and K. H. Tkaczuk (2012). "Update on taxane development: new analogs and new formulations." *Drug Des Devel Ther* **6**: 371–384.
31. Cortes, J. E. and R. Pazdur (1995). "Docetaxel." *J Clin Oncol* **13**(10): 2643–2655.

Figures

PRISMA 2009 Flow Diagram

Figure 1

A schematic flow for the selection of articles included in this meta-analysis.

Figure 2

Forest plot of comparison: overall survival of PD-1/L1 or CTLA-4 inhibitors alone or in combination versus chemotherapy for advanced or metastatic NSCLC patients ($P < 0.001$).

NOTE: Weights and between-subgroup heterogeneity test are from random-effects model

Figure 3

Forest plots of the overall survival of the correlation between first line and non-first line (first line: $P < 0.001$; non-first line: $P < 0.001$).

NOTE: Weights and between-subgroup heterogeneity test are from random-effects model

Figure 4

Forest plots of the overall survival of the correlation among PD-1, PD-L1 and PD-1/L1+CTLA-4 (PD-1: $P < 0.001$; PD-L1: $P < 0.001$; PD-1/L1+CTLA-4: $P = 0.001$).

Figure 5

Forest plots of the overall survival of the correlation among nivolumab, pembrolizumab and atezolizumab (nivolumab: $P < 0.001$; pembrolizumab: $P < 0.001$; atezolizumab: $P < 0.001$).

Figure 6

Forest plots of the overall survival of the correlation between male and female (male: $P < 0.001$; female: $P = 0.008$).

Figure 7

Forest plots of the overall survival of the correlation between age<65 years and age≥65 years (age<65: $P<0.001$; age≥65: $P=0.001$).

Figure 8

Forest plots of the overall survival of the correlation between non-squamous and squamous (non-squamous: $P < 0.001$; squamous: $P < 0.001$).

Figure 9

Forest plots of the overall survival of the correlation between TPS<0.01 and TPS≥0.01 (TPS<0.01: P=0.029; TPS≥0.01: P<0.001).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFig.1.tif](#)
- [SupplementaryFig.2.tif](#)
- [SupplementaryFig.3.tif](#)
- [SupplementaryFig.4.tif](#)
- [SupplementaryFig.5.tif](#)
- [SupplementaryFig.6.tif](#)
- [SupplementaryFig.7.tif](#)
- [SupplementaryFig.8.tif](#)
- [SupplementaryFig.9.tif](#)
- [SupplementaryFig.10.tif](#)
- [SupplementaryFig.11.tif](#)
- [SupplementaryFig.12.tif](#)
- [SupplementaryTable1.doc](#)